AngioDynamics, Inc. Expected to Earn Q3 2018 Earnings of $0.23 Per Share (ANGO)

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at Craig Hallum issued their Q3 2018 earnings per share (EPS) estimates for shares of AngioDynamics in a report released on Monday. Craig Hallum analyst C. Haff forecasts that the brokerage will post earnings per share of $0.23 for the quarter. Craig Hallum also issued estimates for AngioDynamics’ FY2018 earnings at $0.79 EPS.

Other research analysts also recently issued reports about the company. Zacks Investment Research downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $19.00 price target on shares of AngioDynamics in a report on Tuesday, December 27th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $17.50 price target on shares of AngioDynamics in a report on Friday, January 6th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $17.10.

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is the propert of of BBNS. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/markets/angiodynamics-inc-expected-to-earn-q3-2018-earnings-of-0-23-per-share-ango/345551.html.

AngioDynamics (NASDAQ:ANGO) traded down 1.60% on Wednesday, reaching $17.17. The company’s stock had a trading volume of 388,796 shares. AngioDynamics has a one year low of $9.71 and a one year high of $17.64. The stock’s market cap is $626.77 million. The stock has a 50-day moving average of $16.77 and a 200-day moving average of $16.30.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Friday, January 6th. The company reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The business earned $89 million during the quarter. AngioDynamics had a positive return on equity of 4.87% and a negative net margin of 7.91%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 EPS.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is the propert of of BBNS. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/markets/angiodynamics-inc-expected-to-earn-q3-2018-earnings-of-0-23-per-share-ango/345551.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of ANGO. BlackRock Fund Advisors increased its position in AngioDynamics by 6.3% in the second quarter. BlackRock Fund Advisors now owns 1,796,317 shares of the company’s stock worth $25,813,000 after buying an additional 106,151 shares in the last quarter. BlackRock Investment Management LLC increased its position in AngioDynamics by 13.4% in the second quarter. BlackRock Investment Management LLC now owns 124,572 shares of the company’s stock worth $1,790,000 after buying an additional 14,686 shares in the last quarter. Principal Financial Group Inc. increased its position in AngioDynamics by 2.6% in the second quarter. Principal Financial Group Inc. now owns 186,924 shares of the company’s stock worth $2,686,000 after buying an additional 4,689 shares in the last quarter. Prudential Financial Inc. increased its position in AngioDynamics by 2.3% in the second quarter. Prudential Financial Inc. now owns 64,291 shares of the company’s stock worth $924,000 after buying an additional 1,420 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in AngioDynamics by 4.3% in the second quarter. Dimensional Fund Advisors LP now owns 2,968,384 shares of the company’s stock worth $42,655,000 after buying an additional 121,841 shares in the last quarter. 75.72% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

5 Day Chart for NASDAQ:ANGO

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with our FREE daily email newsletter.

 

Latest News

Orioles Talking Contract with Slugger Jose Bautista
Orioles Talking Contract with Slugger Jose Bautista
Criticism During World Series Humorous to Joe Maddon
Criticism During World Series Humorous to Joe Maddon
Los Angeles Dodgers Awaiting Decision by Twins on Brian Dozier
Los Angeles Dodgers Awaiting Decision by Twins on Brian Dozier
Manny Ramirez Returning to Play Baseball in Japan
Manny Ramirez Returning to Play Baseball in Japan
Rajai Davis Anxious to Start Second Stint With Oakland
Rajai Davis Anxious to Start Second Stint With Oakland
Offseason Moves, Rumors and Possible Deals
Offseason Moves, Rumors and Possible Deals


Leave a Reply

 
© 2006-2017 BBNS.